BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17056150)

  • 1. Integrating new targeted agents into the treatment of non-small-cell lung cancer.
    Thatcher N
    Lung Cancer; 2006 Dec; 54 Suppl 2():S25-31. PubMed ID: 17056150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
    Burris HA
    Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
    Patel JD
    Curr Opin Oncol; 2006 Nov; 18(6):609-14. PubMed ID: 16988582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor as a target in cancer therapy.
    Kim ES
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.
    Ettinger DS
    Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting HER1/EGFR: pathway to progress in cancer therapy.
    Oncology (Williston Park); 2007 Dec; 21(14):2 p preceding 1754. PubMed ID: 18247019
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
    Hirsch FR
    Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of targeted therapy in non-small cell lung cancer.
    Maione P; Rossi A; Airoma G; Ferrara C; Castaldo V; Gridelli C
    Crit Rev Oncol Hematol; 2004 Jul; 51(1):29-44. PubMed ID: 15207252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.
    Araújo A; Ribeiro R; Azevedo I; Coelho A; Soares M; Sousa B; Pinto D; Lopes C; Medeiros R; Scagliotti GV
    Oncologist; 2007 Feb; 12(2):201-10. PubMed ID: 17296816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.
    Stella GM; Luisetti M; Inghilleri S; Cemmi F; Scabini R; Zorzetto M; Pozzi E
    Respir Med; 2012 Feb; 106(2):173-83. PubMed ID: 22104541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for non-small cell lung cancer.
    Toloza EM; D'Amico TA
    Semin Thorac Cardiovasc Surg; 2005; 17(3):199-204. PubMed ID: 16253823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
    Eberhard DA; Giaccone G; Johnson BE;
    J Clin Oncol; 2008 Feb; 26(6):983-94. PubMed ID: 18281673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
    Pérez-Soler R
    Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor signaling in non-small-cell lung cancer.
    Semrad TJ; Mack PC
    Clin Lung Cancer; 2012 Mar; 13(2):90-5. PubMed ID: 21959109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
    Sangha R; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.